{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-337594","form_type":"8-K","ticker":"LITS","cik":"0001262104","company_name":"Lite Strategy, Inc.","filed_at":"2021-11-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.862169+00:00","generated_at":"2026-06-28T05:41:17.891703+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"MEI Pharma appoints Sujay Kango to board; Kevan Clemens resigns effective Nov 22, 2021","bullets":["Kevan Clemens resigned from board effective Nov 22, 2021; no disagreement with company.","Sujay Kango appointed to fill vacancy; 25+ years pharma/biotech experience.","Kango received initial option grant of 25,000 shares vesting over three years.","Kango also received pro-rated annual option grant of 33,334 shares vesting monthly over 12 months.","Kango's expertise includes commercial launches; company aims to transition to commercial stage."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-337594","json":"https://secwatch.observer/filing/0001193125-21-337594.json","markdown":"https://secwatch.observer/filing/0001193125-21-337594.md","text":"https://secwatch.observer/filing/0001193125-21-337594.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1262104/000119312521337594/0001193125-21-337594-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1262104/000119312521337594/d261318d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T05:41:17.891703+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7b53397323","claim":"Sujay Kango was appointed as Director at Lite Strategy, Inc..","evidence_excerpt":"On November 22, 2021, the Board appointed Mr. Sujay Kango to fill the vacancy on the Board resulting from the vacancy created by the resignation of Mr. Clemens.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1262104/000119312521337594/0001193125-21-337594-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b72534d728","claim":"Kevan Clemens resigned as Director at Lite Strategy, Inc..","evidence_excerpt":"On November 22, 2021, Mr. Kevan Clemens, a member of the Board of Directors (the “Board”) of MEI Pharma, Inc. (the “Company”) resigned from the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1262104/000119312521337594/0001193125-21-337594-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}